Camizestrant
As of the edition of 20 October 2026, Camizestrant is a small molecule: marketed, first approved in 2026 (EU); acts on ESR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Etcamah
- First approved
- 20 July 2026 (EU)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- AstraZeneca; 2 holders in all
- Registered trials
- 21, 0 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Digestive system; Hormones; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ESR1 | Estrogen receptor | P03372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 8 | 1 | 0 |
| Phase 2 | 6 | 1 | 5 | 0 |
| Phase 3 | 6 | 0 | 6 | 0 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Originator and Lead sponsor of trials | 2018 to now |